Overview

Bioequivalence Study On Pediatric Appropriate Formulation

Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
To determine bioequivalence of a atorvastatin pediatric formulation comparing to the 10 mg commercial atorvastatin calcium tablet formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Atorvastatin
Atorvastatin Calcium